Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$21.65 +6.2%	$19.92	$14.40 ▼ $47.00	$1.35B	1.33	941,105 shs	891,177 shs
DVAX Dynavax Technologies	$9.91 +1.4%	$10.23	$9.22 ▼ $14.63	$1.17B	1.06	2.17 million shs	1.10 million shs
EBS Emergent Biosolutions	$6.76 +3.6%	$5.91	$4.02 ▼ $15.10	$353.89M	2.1	1.77 million shs	1.06 million shs
MNKD MannKind	$3.99 +5.0%	$4.37	$3.63 ▼ $7.63	$1.15B	1.02	2.38 million shs	3.52 million shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	-0.54%	+0.25%	+0.20%	+1.19%	-42.19%
DVAX Dynavax Technologies	-2.20%	-3.93%	-0.31%	-30.11%	-14.52%
EBS Emergent Biosolutions	+3.95%	+4.49%	+1.87%	+18.76%	0.00%
MNKD MannKind	+0.80%	-0.26%	-7.77%	-27.20%	-25.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLDX Celldex Therapeutics	2.764 of 5 stars	4.4	3.0	0.0	2.7	0.0	0.0
DVAX Dynavax Technologies	4.2505 of 5 stars	3.3	1.0	4.7	2.5	1.7	1.9
EBS Emergent Biosolutions	4.2841 of 5 stars	3.5	2.0	4.6	1.4	2.5	1.3
MNKD MannKind	2.5734 of 5 stars	3.6	1.0	0.0	1.0	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDX Celldex Therapeutics	2.89	Moderate Buy	$50.11	131.46% Upside
DVAX Dynavax Technologies	2.50	Moderate Buy	$24.00	142.18% Upside
EBS Emergent Biosolutions	3.00	Buy	$14.33	112.16% Upside
MNKD MannKind	3.29	Buy	$10.33	158.98% Upside

Current Analyst Ratings Breakdown

Latest EBS, MNKD, DVAX, and CLDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/13/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
5/9/2025	CLDX Celldex Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $38.00
5/9/2025	CLDX Celldex Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$36.00 ➝ $31.00
5/9/2025	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$46.00 ➝ $43.00
5/7/2025	DVAX Dynavax Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$33.00 ➝ $31.00
5/6/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
4/28/2025	CLDX Celldex Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$64.00
4/17/2025	DVAX Dynavax Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$12.00 ➝ $10.00
4/10/2025	MNKD MannKind	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$12.00
4/9/2025	MNKD MannKind	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/1/2025	EBS Emergent Biosolutions	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDX Celldex Therapeutics	$7.02M	204.72	N/A	N/A	$11.26 per share	1.92
DVAX Dynavax Technologies	$277.25M	4.29	$0.16 per share	61.70	$4.54 per share	2.18
EBS Emergent Biosolutions	$1.04B	0.35	$1.99 per share	3.39	$8.91 per share	0.76
MNKD MannKind	$285.50M	4.25	$0.15 per share	27.34	($0.29) per share	-13.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDX Celldex Therapeutics	-$157.86M	-$2.70	N/A	N/A	N/A	-2,366.07%	-23.46%	-22.35%	8/6/2025 (Estimated)
DVAX Dynavax Technologies	$27.31M	-$0.52	N/A	20.22	N/A	-20.39%	3.59%	2.20%	8/5/2025 (Estimated)
EBS Emergent Biosolutions	-$190.60M	-$2.71	N/A	3.26	N/A	-13.63%	-0.52%	-0.17%	8/5/2025 (Estimated)
MNKD MannKind	$27.59M	$0.10	39.90	17.35	N/A	10.12%	-32.41%	10.85%	8/6/2025 (Estimated)

Latest EBS, MNKD, DVAX, and CLDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	CLDX Celldex Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	$1.08 million	$0.70 million
5/8/2025	Q1 2025	MNKD MannKind	$0.03	$0.04	+$0.01	$0.04	$75.86 million	$78.35 million
5/7/2025	Q1 2025	EBS Emergent Biosolutions	$0.49	$0.71	+$0.22	$1.19	$218.50 million	$222.20 million
5/6/2025	Q1 2025	DVAX Dynavax Technologies	$0.03	-$0.11	-$0.14	-$0.77	$70.01 million	$68.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
DVAX Dynavax Technologies	N/A	N/A	N/A	N/A	N/A
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDX Celldex Therapeutics	N/A	21.67	21.67
DVAX Dynavax Technologies	0.49	11.93	10.84
EBS Emergent Biosolutions	1.20	6.32	3.51
MNKD MannKind	N/A	2.36	2.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDX Celldex Therapeutics	N/A
DVAX Dynavax Technologies	96.96%
EBS Emergent Biosolutions	78.40%
MNKD MannKind	49.55%

Insider Ownership

Company	Insider Ownership
CLDX Celldex Therapeutics	4.40%
DVAX Dynavax Technologies	2.98%
EBS Emergent Biosolutions	3.20%
MNKD MannKind	3.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDX Celldex Therapeutics	150	66.38 million	63.46 million	Optionable
DVAX Dynavax Technologies	350	120.08 million	116.50 million	Optionable
EBS Emergent Biosolutions	2,420	54.28 million	52.54 million	Optionable
MNKD MannKind	400	303.93 million	294.82 million	Optionable

EBS, MNKD, DVAX, and CLDX Headlines

Recent News About These Companies

Leerink Partners Slashes MannKind Corporation’s (MNKD) Price Target to $7, Keeps a Buy Rating

June 24 at 4:18 PM | insidermonkey.com

MannKind Corporation (NASDAQ:MNKD) Receives Consensus Rating of "Buy" from Brokerages

June 24 at 3:01 AM | americanbankingnews.com

MannKind Corporation (NASDAQ:MNKD) Given Average Recommendation of "Buy" by Brokerages

June 24 at 2:59 AM | marketbeat.com

Leerink Partnrs Analysts Cut Earnings Estimates for MannKind

June 21 at 1:35 AM | americanbankingnews.com

MannKind FY2026 EPS Forecast Decreased by Leerink Partnrs

June 19, 2025 | marketbeat.com

MannKind (NASDAQ:MNKD) Reaches New 1-Year Low - Should You Sell?

June 17, 2025 | marketbeat.com

MannKind’s Afrezza: A Significantly Undervalued Investment Opportunity with Promising Clinical Data

June 16, 2025 | tipranks.com

MannKind (NASDAQ:MNKD) Upgraded by Wall Street Zen to "Buy" Rating

June 14, 2025 | marketbeat.com

Insider Selling: MannKind Co. (NASDAQ:MNKD) Director Sells 64,085 Shares of Stock

June 11, 2025 | insidertrades.com

Insider Sell: Steven Binder Sells 64,085 Shares of MannKind Corp (MNKD)

June 10, 2025 | gurufocus.com

MannKind Co. (NASDAQ:MNKD) Director Sells 64,085 Shares

June 10, 2025 | marketbeat.com

MannKind’s Strategic Growth Potential and Market Positioning: A Buy Recommendation

June 10, 2025 | tipranks.com

MannKind (NASDAQ:MNKD) Sets New 1-Year Low - Time to Sell?

June 10, 2025 | marketbeat.com

Cantor Fitzgerald Estimates MannKind FY2026 Earnings

June 10, 2025 | marketbeat.com

MannKind Corp (MNKD) to Showcase Inhaled Insulin at ADA's 85th Scientific Sessions | MNKD stock news

June 9, 2025 | gurufocus.com

MannKind Corporation to Showcase Inhaled Insulin Innovations at ADA's 85th Scientific Sessions

June 9, 2025 | quiverquant.com

MannKind to present inhaled insulin study at ADA event

June 9, 2025 | investing.com

MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23

June 9, 2025 | globenewswire.com

MannKind (NASDAQ:MNKD) Stock Rating Lowered by Wall Street Zen

June 7, 2025 | marketbeat.com

180 Wealth Advisors LLC Has $11.04 Million Holdings in MannKind Co. (NASDAQ:MNKD)

June 2, 2025 | marketbeat.com

MannKind Co. (NASDAQ:MNKD) Given Average Recommendation of "Buy" by Brokerages

May 31, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EBS, MNKD, DVAX, and CLDX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

$21.65 +1.26 (+6.18%)

Closing price 04:00 PM Eastern

Extended Trading

$22.16 +0.52 (+2.38%)

As of 07:11 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Dynavax Technologies NASDAQ:DVAX

$9.91 +0.14 (+1.43%)

Closing price 04:00 PM Eastern

Extended Trading

$9.90 -0.01 (-0.10%)

As of 07:55 PM Eastern

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Emergent Biosolutions NYSE:EBS

$6.76 +0.24 (+3.62%)

Closing price 03:59 PM Eastern

Extended Trading

$6.79 +0.04 (+0.56%)

As of 07:35 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

MannKind NASDAQ:MNKD

$3.99 +0.19 (+5.00%)

Closing price 04:00 PM Eastern

Extended Trading

$3.92 -0.07 (-1.75%)

As of 07:56 PM Eastern

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time